Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN)

被引：0
|
作者：
Glisson, Bonnie S.
Tseng, Jennifer
Marur, Shanthi
Shin, Dong M.
Murphy, Barbara A.
Cohen, Ezra E. W.
Thomas, Christopher Y.
Willey, Richard
Cosaert, Jan
William, William Nassib
Harun, Nusrat
Lee, J. Jack
Haddad, Robert I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Orlando, FL USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA
[6] Univ Chicago Med Ctr, Chicago, IL USA
[7] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[8] ImClone Syst LLC, Bridgewater, NJ USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[10] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6030
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
    Ferrarotto, Renata
    William, William N., Jr.
    Tseng, Jennifer E.
    Marur, Shanthi
    Shin, Dong M.
    Murphy, Barbara
    Cohen, Ezra E. W.
    Thomas, Christopher Y.
    Willey, Richard
    Cosaert, Jan
    Harun, Nusrat
    Lee, J. Jack
    Wistuba, Ignacio W.
    Haddad, Robert I.
    Glisson, Bonnie S.
    ORAL ONCOLOGY, 2018, 82 : 83 - 90
  • [2] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [4] An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD)
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher, J.
    Gruenwald, V
    Rethwisch, V
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2012, 35 : 153 - 153
  • [5] Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
    Bauman, Julie E.
    Saba, Nabil F.
    Roe, Denise
    Bauman, Jessica R.
    Kaczmar, John
    Bhatia, Aarti
    Muzaffar, Jameel
    Julian, Ricklie
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor
    Giri, Anshu
    Burtness, Barbara
    Centuori, Sara
    Caulin, Carlos
    Klein, Robert
    Saboda, Kathylynn
    Obara, Stefanie
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3851 - +
  • [6] A randomized phase II trial of the MET inhibitor tivantinib plus cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer
    Vokes, Everett E.
    Worden, Francis P.
    Adkins, Douglas
    Bauman, Julie E.
    Lim, Dean
    Sukari, Ammar
    Rao, Krishna A.
    Wagner, Stephanie Ann
    Curtis, Kelly Kevelin
    Gitlitz, Barbara J.
    Price, Katharine Andress Rowe
    Wade, James Lloyd
    Villaflor, Victoria Meucci
    De Souza, Jonas A.
    Karrison, Theodore
    Stadler, Walter Michael
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Results of phase II trial unicancer ORL03.
    Fayette, Jerome
    Guigay, Joel
    Le Toumeau, Christophe
    Degardin, Marian
    Peyrade, Frederic
    Orlandini, Florence
    Buffard, Karine
    Bellera, Carine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Fayette, J.
    Lefebvre, G.
    Posner, M. R.
    Bauman, J.
    Salas, S.
    Even, C.
    Saada-Bouzid, E.
    Seiwert, T.
    Colevas, D.
    Calmels, F.
    Zerbib, R.
    Chammard, A. Boyer
    Cohen, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 374 - 374
  • [9] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345